Literature DB >> 16288289

The Akt of translational control.

Davide Ruggero1, Nahum Sonenberg.   

Abstract

The oncogene AKT (also called protein kinase B (PKB)) signals to the translational machinery, and activation of protein synthesis by Akt is associated with cancer formation. Akt directly stimulates the activity of translation initiation factors and upregulates ribosome biogenesis. Activation of protein synthesis by Akt is phylogenetically conserved from Drosophila to humans, and is important for regulating cell growth, proliferation and cell survival. Consequently, translation defects due to aberrant Akt activation may be a crucial mechanism leading to tumorigenesis. However, few in vivo studies have established a causative role for aberrant protein synthesis control in cancer. A major challenge in the future will be to identify the specific mRNAs regulated at the level of translation control directly relevant for cellular transformation. In this review, we highlight and discuss the emerging molecular and genetic evidence that support a model by which deregulation of specific or global protein synthesis contributes to cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288289     DOI: 10.1038/sj.onc.1209098

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  81 in total

1.  AMPK protects proximal tubular cells from stress-induced apoptosis by an ATP-independent mechanism: potential role of Akt activation.

Authors:  Wilfred Lieberthal; Leiqing Zhang; Vimal A Patel; Jerrold S Levine
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-28

2.  Arsenite causes down-regulation of Akt and c-Fos, cell cycle dysfunction and apoptosis in glutathione-deficient cells.

Authors:  Geetha M Habib
Journal:  J Cell Biochem       Date:  2010-05-15       Impact factor: 4.429

3.  Systematic identification and functional screens of uncharacterized proteins associated with eukaryotic ribosomal complexes.

Authors:  Tracey C Fleischer; Connie M Weaver; K Jill McAfee; Jennifer L Jennings; Andrew J Link
Journal:  Genes Dev       Date:  2006-05-15       Impact factor: 11.361

Review 4.  Drosophila follicle cells: morphogenesis in an eggshell.

Authors:  Xiaodong Wu; Pradeep Singh Tanwar; Laurel A Raftery
Journal:  Semin Cell Dev Biol       Date:  2008-01-20       Impact factor: 7.727

5.  Akt activation enhances ribosomal RNA synthesis through casein kinase II and TIF-IA.

Authors:  Le Xuan Truong Nguyen; Beverly S Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

6.  Dynamic changes in ribosome-associated proteome and phosphoproteome during deoxynivalenol-induced translation inhibition and ribotoxic stress.

Authors:  Xiao Pan; Douglas A Whitten; Curtis G Wilkerson; James J Pestka
Journal:  Toxicol Sci       Date:  2013-11-27       Impact factor: 4.849

7.  Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling.

Authors:  Oak D Jo; Jheralyn Martin; Andrew Bernath; Janine Masri; Alan Lichtenstein; Joseph Gera
Journal:  J Biol Chem       Date:  2008-06-18       Impact factor: 5.157

8.  Repeated aerosol delivery of carboxyl-terminal modulator protein suppresses tumor in the lungs of K-rasLA1 mice.

Authors:  Soon-Kyung Hwang; Hwang-Tae Lim; Arash Minai-Tehrani; Eun-Sun Lee; Jongmin Park; Seung Bum Park; George R Beck; Myung-Haing Cho
Journal:  Am J Respir Crit Care Med       Date:  2009-03-12       Impact factor: 21.405

9.  Natural sphingadienes inhibit Akt-dependent signaling and prevent intestinal tumorigenesis.

Authors:  Henrik Fyrst; Babak Oskouian; Padmavathi Bandhuvula; Yaqiong Gong; Hoe Sup Byun; Robert Bittman; Andrew R Lee; Julie D Saba
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

10.  Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.

Authors:  Morris E Feldman; Beth Apsel; Aino Uotila; Robbie Loewith; Zachary A Knight; Davide Ruggero; Kevan M Shokat
Journal:  PLoS Biol       Date:  2009-02-10       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.